THE DNA-DAMAGING DRUG CYPROTERONE-ACETATE CAUSES GENE-MUTATIONS AND INDUCES GLUTATHIONE-S-TRANSFERASE-P IN THE LIVER OF FEMALE BIG-BLUE(TM)TRANSGENIC F344 RATS
O. Krebs et al., THE DNA-DAMAGING DRUG CYPROTERONE-ACETATE CAUSES GENE-MUTATIONS AND INDUCES GLUTATHIONE-S-TRANSFERASE-P IN THE LIVER OF FEMALE BIG-BLUE(TM)TRANSGENIC F344 RATS, Carcinogenesis, 19(2), 1998, pp. 241-245
The gestagenic and antiandrogenic drug cyproterone acetate (CPA) is mi
togenic, tumorigenic and induces DNA-adducts and DNA-repair synthesis
in rat liver. Thus CPA is expected to be mutagenic, However in pike mu
tagenicity test systems were negative, To examine whether CPA induces
mutations in rat liver, the in vivo mutation assay based on Big Blue(T
M) transgenic F334 rats was employed, Single oral doses of 25, 50, 75,
100 and 200 mg CPA/kg b.w. respectively were administered to female B
ig Blue(TM) rats, Six weeks after treatment, liver DNA was assayed for
mutations, At the highest dose, 200 mg CPA/kg b.w., the frequency of
(17 +/- 4) x 10(-6) spontaneous mutations was increased to a maximum o
f (80 +/- 8) x 10(6) mutations. One-hundred and 75 mg CPA/kg b.w. resu
lted in mutation frequencies of (35 +/- 5) and (27 +/- 5) x 10(-6), re
spectively, The mutation frequency at doses of 50 and 25 mg CPA/kg b.
cv. was similar to that of vehicle treated controls. Statistical analy
sis of the dose-effect relationship revealed that it was not possible
to decide whether a threshold dose exists or not, DNA adducts were ana
lyzed by the P-32-postlabelling technique, The total level of the majo
r and the two minor adducts observed in the autoradiograms increased b
etween doses of 25 to 75 mg CPA/kg b.w. to a maximum of similar to 12
000 +/- 3000 adducts per 10(9) nucleotides. The level did not further
increase significantly with 100 and 200 mg CPA/kg b.w. After CPA treat
ment no preneoplastic liver foci mere observed, However, single glutat
hione-S-transferase placental form (GST-P) positive hepatocytes were o
bserved and the frequency was dependent on the dose. These cells are n
ot supposed to represent initiated cells, since they occurred only tra
nsiently after 6 weeks and disappeared thereafter completely. In concl
usion, our results demonstrate that CPA is mutagenic in vivo. The muta
tion frequency increased at high CPA doses, when the increase of the D
NA adduct formation had already ceased. This suggests that the mitogen
ic activity of CPA is required to express the mutations.